Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Boundless Bio on the offering, and Cooley advised the underwriters. Boundless Bio, Inc. (Nasdaq: BOLD) a clinical...
Boundless Bio’s $100 Million IPO
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
UNITY Biotechnology’s $45 Million Shares Offering
Latham & Watkins represented UNITY Biotechnology in the transaction. UNITY Biotechnology, Inc. (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has...
Amgen’s $3 Billion Senior Unsecured Notes Offerings
Latham & Watkins represented Amgen in the offerings, while Shearman & Sterling represented represented the underwriters. Amgen Inc. executed a senior unsecured notes offerings consisting of US$1,250,000,000 4.050%...
SK Capital’s Acquisition of Valtris Specialty Chemicals
Latham & Watkins represented SK Capital in the transaction. SK Capital Partners, a New York-based private investment firm focused exclusively on the specialty chemicals, materials, and...
Amgen’s $4 Billion Senior Unsecured Notes Offerings
Latham & Watkins represented Amgen in the offerings. Amgen Inc., one of the world’s leading biotechnology companies, priced on February 17, 2022, a senior unsecured notes...
Archimed’s Acquisition of a Majority Stake in SuanFarma
Latham & Watkins and PwC Deals advised ArchiMed on the deal while Allen & Overy represented CG. Suanfarma is a Spanish company specialising in the development,...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...